Effects and side effects of strong-acting opioids for the treatment of cancer-related pain: a study of the role of differences in metabolism (degradation) of the medicine and differences in genes

Effects en side effects of strong-acting opioids: a study on the role of pharmacokinetic and pharmacogenetic heterogeneity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29058

Enrollment

350

Registered

2014-01-06

Start date

2010-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related pain Strong-acting opioids Pharmacogenetic(s) Pharmacokinetics Opioid rotation Pain control Side effects Kanker gerelateerde pijn sterk werkende opioiden Farmacogenetica Farmacokinetiek Opioid rotatie Pijncontrole Bijwerkingen

Interventions

Treatment is given according to physician's choice Blood samples drawn for pharmacogenetic analysis in all patients Blood samples drawn for pharmacokinetic analysis in patients who consent only

Eligibility

Inclusion criteria

Inclusion criteria: Hospitalized patients treated with strong-acting opioids for moderate to severe cancer related nociceptive pain. Starting treatment with strong-acting opioids or needing adjustment of current treatment

Exclusion criteria

Exclusion criteria: Estimated duration of hospitalisation < 72 hours

Design outcomes

Primary

Measure	Time frame
- Are variations in pharmacogenetics and/or pharmacokinetics related to insufficient pain control and/or the occurrence of intolerable side effects? - To study the role of demographic and clinical factors on outcome of treatment - To study how the factors mentioned above affect the outcome of opioid rotation	—

Contacts

Public ContactA, Oosten

P.O. Box 5201, 3008 AE Rotterdam, The Netherlands

a.oosten@erasmusmc.nl+31 10 704 19 06

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)